(Alliance News) - GlaxoSmithKline on Monday said a study of ovarian cancer treatment Zejula met its primary endpoint of a statistically significant improvement in progression free survival for women regardless of their biomarker status.
The Phase 3 randomized, double-blind, placebo-controlled, study of Zejula, or Niraparib, as a maintenance therapy in patients with first-line ovarian cancer following platinum-based chemotherapy met its primary endpoint, the drug maker said, adding that the safety and tolerability profile of the drug was consistent with previous clinical trials.
"Almost 300,000 women around the world are diagnosed with ovarian cancer every year, yet only about 15% of patients are currently eligible to receive PARP inhibitors as their initial therapy. These exciting data demonstrate that Zejula has the potential to significantly benefit even more women with this devastating cancer," said Chief Scientific Officer and Research & Development President Hal Barron.
Shares in Glaxo were trading 0.2% higher at 1,626.20 pence each on Monday morning.